Brief: Tiumbio To Initiate Phase 2 Trial Of Tu2218 For Cancer
11/03/2024 12:55
March 11 (Reuters) - TiumBio Co Ltd 321550.KQ :
* TIUMBIO TO INITIATE PHASE 2 TRIAL OF TU2218 FOR CANCER
* TIUMBIO CO LTD - TIUMBIO WILL PURSUE THREE INDICATIONS FOR
TU2218 COMBINATION CLINICAL TRIAL WITH PEMBROLIZUMAB
* TIUMBIO CO LTD - TU2218 DEMONSTRATED A FAVORABLE SAFETY
AND A
SYNERGETIC EFFECT WITH IMMUNO-ONCOLOGY DRUGS IN PRECLINICAL
STUDIES
* TIUMBIO CO - CURRENTLY CONDUCTING A PHASE 1B CLINICAL
TRIAL OF
TU2218 IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB) IN ADVANCED
SOLID TUMORS IN U.S.
Source text for Eikon: ID:nPn7GnVtCa
Further company coverage: 321550.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TiumBio Co
See all newsBrief: TiumBio And Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial Of 'Merigolix For Uterine Fibroids
Brief: TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab
Brief: TiumBio Submits CTA For Phase 1b Clinical Trial Of TU7710
Brief: Tiumbio To Initiate Phase 2 Trial Of Tu2218 For Cancer
Brief: Tiumbio And Hansoh Pharma Announce Clinical Trial Approval Of 'HS-10518/TU2670' From NMPA In China